Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VRTX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Evaluation of Pain Treatment After Total Knee Arthroplasty NCT07538570 · Pain Suzetrigine, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 4 | Completed was active, not recruiting | 66 | Oct 12, 2026 | Registry ↗ |
| Nov 12, 2026 | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Dise… NCT06747572 · Autosomal Dominant Polycystic Kidney Disease (ADPKD) | VRTX Vertex Pharmaceuticals Incorporated | — | Active, not recruiting | 401 | Dec 31, 2026 | Registry ↗ |
| Oct 30, 2026 | Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose NCT07868926 · Autosomal Dominant Polycystic Kidney Disease (ADPKD) 14C-VX-407 | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting was not yet recruiting | 8 | Dec 15, 2026 | Registry ↗ |
| Oct 30, 2026 | Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membr… NCT07204275 · Primary Membranous Nephropathy Povetacicept, Tacrolimus | VRTX Vertex Pharmaceuticals Incorporated | Phase 2/3 | Recruiting | 176 | Dec 29, 2028 | Registry ↗ |
| Oct 30, 2026 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Pain… NCT06696443 · Diabetic Peripheral Neuropathic Pain Suzetrigine | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Active, not recruiting | 455 | Jan 25, 2027 | Registry ↗ |
| Oct 29, 2026 | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis NCT07501702 · Myasthenia Gravis, Generalized Povetacicept, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 2 | Active, not recruiting was recruiting | 34 | Mar 2, 2029 | Registry ↗ |
| Oct 27, 2026 | A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation NCT07813039 · Cystic Fibrosis VX-581 | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Active, not recruiting | 16 | Oct 27, 2026 | Registry ↗ |
| Oct 27, 2026 | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in S… NCT05331183 · Cystic Fibrosis ELX/TEZ/IVA, IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Active, not recruiting | 297 | Apr 6, 2027 | Registry ↗ |
| Oct 26, 2026 | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinu… NCT05312879 · Proteinuric Kidney Disease VX-147, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 2/3 | Active, not recruiting | 522 | Jun 2, 2028 | Registry ↗ |
| Oct 22, 2026 | A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compare… NCT07890909 · Immunoglobulin A Nephropathy Povetacicept, Sibeprenlimab | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Not yet recruiting | 40 | Dec 12, 2027 | Registry ↗ |
| Oct 19, 2026 | A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A… NCT07807995 · Immunoglobulin A Nephropathy Povetacicept | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Enrolling by invitation | 605 | Dec 28, 2029 | Registry ↗ |
| Oct 19, 2026 | Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis NCT07283770 · Cystic Fibrosis VX-581, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | 152 | Jul 12, 2027 | Registry ↗ |
| Oct 15, 2026 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuro… NCT06628908 · Diabetic Peripheral Neuropathic Pain Suzetrigine, Placebo (matched to SUZ) | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | 1,100 | May 31, 2027 | Registry ↗ |
| Oct 15, 2026 | Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 1… NCT05882357 · Cystic Fibrosis ELX/TEZ/IVA, IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Completed | 67 | Sep 4, 2025 | Registry ↗ |
| Oct 14, 2026 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I NCT06926621 · Myotonic Dystrophy Type 1 (DM1) VX-670 | VRTX Vertex Pharmaceuticals Incorporated | Phase 2 | Enrolling by invitation | 44 | Jan 30, 2029 | Registry ↗ |
| Oct 9, 2026 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes NCT05791201 · Type 1 Diabetes VX-264 | VRTX Vertex Pharmaceuticals Incorporated | Phase 1/2 | Active, not recruiting | 7 | Mar 12, 2027 | Registry ↗ |
| Oct 9, 2026 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) NCT05668741 · Cystic Fibrosis VX-522 mRNA therapy, IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 1/2 | Completed | 26 | Apr 21, 2026 | Registry ↗ |
| Oct 9, 2026 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy NCT05444257 · Cystic Fibrosis VX-121/TEZ/D-IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Active, not recruiting | 822 | Oct 30, 2026 | Registry ↗ |
| Sep 30, 2026 | Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives NCT07792408 · Autosomal Dominant Polycystic Kidney Disease (ADPKD) VX-407, LNG/EE | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | 148 | Mar 11, 2027 | Registry ↗ |
| Sep 23, 2026 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants NCT07437105 · Cystic Fibrosis VX-272, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | 160 | Jun 26, 2027 | Registry ↗ |
| Sep 21, 2026 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) NCT07161037 · Autosomal Dominant Polycystic Kidney Disease (ADPKD) VX-407 | VRTX Vertex Pharmaceuticals Incorporated | Phase 2 | Active, not recruiting | 26 | Jul 22, 2027 | Registry ↗ |
| Sep 16, 2026 | A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease NCT03745287 · Sickle Cell Disease, Hematological Diseases Exa-cel | VRTX Vertex Pharmaceuticals Incorporated | Phase 2/3 | Completed | 63 | Jul 7, 2025 | Registry ↗ |
| Sep 9, 2026 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants NCT07378865 · Pain Suzetrigine | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | 13 | Aug 17, 2026 | Registry ↗ |
| Sep 1, 2026 | A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes NCT04786262 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness VX-880, VX-017 | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | 57 | Dec 31, 2027 | Registry ↗ |
| Aug 20, 2026 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidit… NCT06794996 · Proteinuric Kidney Disease Inaxaplin | VRTX Vertex Pharmaceuticals Incorporated | Phase 2 | Completed | 42 | Jul 20, 2026 | Registry ↗ |
| Aug 20, 2026 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) NCT06185764 · Myotonic Dystrophy Type 1 (DM1) VX-670, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 1/2 | Active, not recruiting | 47 | Feb 2, 2027 | Registry ↗ |
| Aug 18, 2026 | Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants NCT07570069 · Pain Suzetrigine, Efavirenz | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | 18 | Jul 16, 2026 | Registry ↗ |
| Aug 11, 2026 | A Long-term Follow-up Study in Participants Who Received CTX001 NCT04208529 · Beta-Thalassemia, Thalassemia CTX001 | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Enrolling by invitation | 160 | Sep 30, 2039 | Registry ↗ |
| Aug 10, 2026 | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis NCT06154447 · Cystic Fibrosis VX-828, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | 165 | Jul 10, 2026 | Registry ↗ |
| Jul 20, 2026 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral… NCT07231419 · Diabetic Peripheral Neuropathic Pain Suzetrigine, Placebo (matched to SUZ) | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | 734 | Apr 6, 2027 | Registry ↗ |
| Jul 1, 2026 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-… NCT05356195 · Beta-Thalassemia, Thalassemia CTX001 | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Active, not recruiting | 16 | Nov 14, 2027 | Registry ↗ |
| Jul 1, 2026 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disea… NCT05329649 · Sickle Cell Disease, Hydroxyurea Failure CTX001 | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Active, not recruiting | 13 | Jun 6, 2027 | Registry ↗ |
| Jun 8, 2026 | A Phase 1, First-in-human Study of VX-433 NCT07584434 · Narcolepsy Type 1 (NT1) VX-433, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | 118 | Mar 5, 2027 | Registry ↗ |
| Jun 5, 2026 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Month… NCT06460506 · Cystic Fibrosis ELX/TEZ/IVA, IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Active, not recruiting | 50 | Sep 30, 2027 | Registry ↗ |
| Jun 1, 2026 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy NCT06619860 · Diabetic Peripheral Neuropathic Pain VX-993, Pregabalin | VRTX Vertex Pharmaceuticals Incorporated | Phase 2 | Recruiting | 300 | Mar 25, 2027 | Registry ↗ |
| May 28, 2026 | A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy NCT06619847 · Acute Pain VX-993, HB/APAP | VRTX Vertex Pharmaceuticals Incorporated | Phase 2 | Completed | 367 | May 27, 2025 | Registry ↗ |
| May 28, 2026 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Yea… NCT05422222 · Cystic Fibrosis VX-121/TEZ/D-IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Active, not recruiting | 210 | Jun 30, 2030 | Registry ↗ |
| Apr 29, 2026 | Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibro… NCT05844449 · Cystic Fibrosis VNZ/TEZ/D-IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Enrolling by invitation | 174 | Jul 30, 2029 | Registry ↗ |
| Apr 2, 2026 | Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy… NCT07349394 · Cystic Fibrosis VNZ/TEZ/D-IVA, Rosuvastatin | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | 18 | Feb 28, 2026 | Registry ↗ |
| Mar 30, 2026 | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants NCT07074327 · Autosomal Dominant Polycystic Kidney Disease (ADPKD) VX-407, LNG/EE | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | 74 | Feb 20, 2026 | Registry ↗ |
| Mar 27, 2026 | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Particip… NCT07022119 · Autosomal Dominant Polycystic Kidney Disease (ADPKD) VX-407, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | 32 | Feb 24, 2026 | Registry ↗ |
| Mar 25, 2026 | Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Ce… NCT05951205 · Sickle Cell Disease Exa-cel | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Withdrawn | 0 | Dec 31, 2033 | Registry ↗ |
| Mar 23, 2026 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a K… NCT06832410 · Type 1 Diabetes, Kidney Transplant Biological/Vaccine | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | 10 | Sep 17, 2026 | Registry ↗ |
| Mar 23, 2026 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Depen… NCT05477563 · Beta-Thalassemia, Thalassemia CTX001 | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | 26 | Jun 9, 2027 | Registry ↗ |
| Mar 3, 2026 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Y… NCT05153317 · Cystic Fibrosis ELX/TEZ/IVA, IVA | VRTX Vertex Pharmaceuticals Incorporated | Phase 3 | Completed | 71 | Jan 29, 2026 | Registry ↗ |
| Dec 31, 2025 | Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF) NCT06506773 · Cystic Fibrosis | VRTX Vertex Pharmaceuticals Incorporated | — | Completed | 79 | Nov 27, 2025 | Registry ↗ |
| Dec 17, 2025 | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalasse… NCT03655678 · Beta-Thalassemia, Thalassemia CTX001 | VRTX Vertex Pharmaceuticals Incorporated | Phase 2/3 | Completed | 59 | Nov 13, 2025 | Registry ↗ |
| Dec 15, 2025 | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain Afte… NCT06887972 · Acute Pain Suzetrigine | VRTX Vertex Pharmaceuticals Incorporated | Phase 4 | Completed | 100 | Oct 24, 2025 | Registry ↗ |
| Dec 15, 2025 | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain Afte… NCT06887959 · Acute Pain Suzetrigine | VRTX Vertex Pharmaceuticals Incorporated | Phase 4 | Completed | 47 | Oct 27, 2025 | Registry ↗ |
| Oct 1, 2025 | Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) NCT06176196 · Painful Lumbosacral Radiculopathy VX-548, Placebo | VRTX Vertex Pharmaceuticals Incorporated | Phase 2 | Completed | 218 | Oct 2, 2024 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances